CLINICAL TRIAL SUMMARY

MDACC Study No:GOG 0268 (clinicaltrials.gov NCT No: NCT01196429)
Title:A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: 683864, IND #61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus (CCI-779) Consolidation as First-line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Principal Investigator:Jubilee Brown
Treatment Agent:Carboplatin; Paclitaxel; Temsirolimus
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the combination of
paclitaxel, carboplatin, and temsirolimus can help to control Stage III or
Stage IV clear cell cancer of the ovary in patients in the U.S. versus patients
in Japan. The safety of this study drug combination will also be studied.

If you are alcohol intolerant, docetaxel will be given instead of paclitaxel.

Hide details for General InformationGeneral Information

Disease Group:Ovary
Phase of Study:Phase II
Treatment Agents:Carboplatin
Paclitaxel
Temsirolimus
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Gynecologic Oncology Group
National Cancer Institute
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jubilee Brown
Dept:Cancer Medicine
For Clinical Trial Enrollment:713-792-9599
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults